Background BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based
on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to …

Aim The review summarizes the recent empirical evidence on the efficacy, safety, and
community perception of malaria vaccines in Africa. Methods Academic Search Complete …

Malaria, caused by Plasmodium species, remains a major global health concern, causing
millions of deaths annually. While the introduction of the RTS, S vaccine has shown promise …

Malaria is a major cause of morbidity and mortality. Immunity is acquired but is suboptimal,
being slow to develop and incomplete. An inadequate understanding of natural immunity …

Background A blood-stage vaccine targeting the erythrocytic-stages of the malaria parasite
Plasmodium falciparum could play a role to protect against clinical disease. Antibodies …

Extensive control efforts have significantly reduced malaria cases and deaths over the past
two decades, but in recent years, coupled with the COVID-19 pandemic, success has …

Malaria, caused by apicomplexan parasite, is an old disease and continues to be a major
public health threat in many countries. This article aims to present different aspects of …

Background A vaccine targeting the erythrocyte stages of Plasmodium falciparum could play
a role in preventing clinical disease. BK-SE36 is a promising malaria vaccine candidate that …

Malaria is a life threatening disease caused by microscopic parasites called Plasmodium
that are transmitted to human beings by mosquitoes. Single celled Eukaryotic plasmodium …

Background BK-SE36 is blood-stage malaria vaccine candidate that is undergoing clinical
trials. Here, the safety and immunogenicity of BK-SE36 with a novel adjuvant, CpG-ODN …